Cytokinetics(DE:KK3A)
€52.46+3.69 (+7.57%)
DE:KK3A
Cytokinetics stock forecast
€52.46
At close:+3.69 (+7.57%)
Cytokinetics (KK3A) Stock Forecast & Price Target
4 Followers
KK3A Analyst Ratings
Strong Buy
16Buy1Hold0Sell
Based on 17 analysts giving stock ratings to Cytokinetics in the past 3 months
KK3A Stock 12 Month Forecast
Average Price Target
€95.77▲(82.56% Upside)Based on 17 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is EUR 95.77 with a high forecast of EUR 125.54 and a low forecast of EUR 69.95. The average price target represents a 82.56% change from the last price of EUR 52.46.
Past 12 Months12 Month ForecastJan2026Oct2026
High€125.54
Average€95.77
Low€69.95
Highest Price TargetHighest€125.54Average Price Target€95.77Lowest Price TargetLowest€69.95
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Joseph Pantginis | H.C. Wainwright | €125.54 | buy | 139.31%Upside | Reiterated | 11/09/26 | ||
| Eric Joseph | Citi | €88.78→€94.16 | buy | 79.48%Upside | Reiterated | 11/06/26 | ||
| Srikripa Devarakonda | Truist Financial | €100.43 | buy | 91.45%Upside | Reiterated | 11/06/26 | ||
| Maxwell Skor | Morgan Stanley | €92.36 | buy | 76.07%Upside | Assigned | 11/05/26 | ||
| Emily Field | Barclays | €98.64 | buy | 88.03%Upside | Reiterated | 11/05/26 | ||
| Yasmeen Rahimi | Piper Sandler | €95.95 | buy | 82.90%Upside | Reiterated | 11/05/26 | ||
| Yanan Zhu | Wells Fargo | €94.16 | buy | 79.48%Upside | Reiterated | 11/05/26 | ||
| James Condulis | Stifel Nicolaus | €96.85 | buy | 84.61%Upside | Reiterated | 11/05/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | €92.36→€89.67 | buy | 70.94%Upside | Reiterated | 11/05/26 | ||
| Cory Kasimov | Evercore ISI | €89.67 | buy | 70.94%Upside | Reiterated | 11/05/26 | ||
| Jason Zemansky | Bank of America Securities | €72.64→€69.95 | hold | 33.33%Upside | Reiterated | 11/04/26 | ||
| Leonid Timashev | RBC Capital | €101.33 | buy | 93.16%Upside | Reiterated | 11/04/26 | ||
| Ashwani Verma | UBS | €103.13→€93.26 | buy | 77.78%Upside | Reiterated | 10/15/26 | ||
| Alethia Young | William Blair | ― | buy | ― | Initiated | 10/15/26 | ||
| Tessa Romero | J.P. Morgan | ― | buy | ― | Reiterated | 10/14/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Joseph PantginisH.C. Wainwright | BuyReiterated€125.54 | 11/09/26 | 139.31%Upside | ||
| Eric JosephCiti | BuyReiterated€88.78→€94.16 | 11/06/26 | 79.48%Upside | ||
| Srikripa DevarakondaTruist Financial | BuyReiterated€100.43 | 11/06/26 | 91.45%Upside | ||
| Maxwell SkorMorgan Stanley | BuyAssigned€92.36 | 11/05/26 | 76.07%Upside | ||
| Emily FieldBarclays | BuyReiterated€98.64 | 11/05/26 | 88.03%Upside | ||
| Yasmeen RahimiPiper Sandler | BuyReiterated€95.95 | 11/05/26 | 82.90%Upside | ||
| Yanan ZhuWells Fargo | BuyReiterated€94.16 | 11/05/26 | 79.48%Upside | ||
| James CondulisStifel Nicolaus | BuyReiterated€96.85 | 11/05/26 | 84.61%Upside | ||
| Unknown AnalystLeerink PartnersNot Ranked | BuyReiterated€92.36→€89.67 | 11/05/26 | 70.94%Upside | ||
| Cory KasimovEvercore ISI | BuyReiterated€89.67 | 11/05/26 | 70.94%Upside | ||
| Jason ZemanskyBank of America Securities | HoldReiterated€72.64→€69.95 | 11/04/26 | 33.33%Upside | ||
| Leonid TimashevRBC Capital | BuyReiterated€101.33 | 11/04/26 | 93.16%Upside | ||
| Ashwani VermaUBS | BuyReiterated€103.13→€93.26 | 10/15/26 | 77.78%Upside | ||
| Alethia YoungWilliam Blair | BuyInitiated | 10/15/26 | ― | ||
| Tessa RomeroJ.P. Morgan | BuyReiterated | 10/14/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Cytokinetics
3 Months
Success Rate16/26 ratings generated profit
62%
Average Return
+21.94%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +21.94% per trade.
1 Year
Success Rate36/53 ratings generated profit
68%
Average Return
+32.87%
Copying Salim Syed's trades and holding each position for 1 Year would result in 67.92% of your transactions generating a profit, with an average return of +32.87% per trade.
2 Years
Success Rate21/28 ratings generated profit
75%
Average Return
+22.61%
Copying Jason Butler's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +22.61% per trade.
KK3A Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 12 | 18 | 25 |
| Buy | 22 | 26 | 19 | 17 | 2 |
| Hold | 3 | 5 | 4 | 4 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 30 | 38 | 35 | 39 | 29 |
In the current month, KK3A has received 27 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. KK3A average Analyst price target in the past 3 months is 95.77.
KK3A Financial Forecast
High€-0.81
Consensus€-1.26
Low€-1.44
KK3A Earnings Forecast
Next quarter’s earnings estimate for KK3A is -EUR 1.26 with a range of -EUR 1.44 to -EUR 0.81. The previous quarter’s EPS was -EUR 1.23. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€73.8M
Consensus€57.6M
Low€47.4M
KK3A Sales Forecast
Next quarter’s sales forecast for KK3A is EUR 57.55M with a range of EUR 47.44M to EUR 73.82M. The previous quarter’s sales results were EUR 42.58M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
KK3A Stock Forecast FAQ
What is DE:KK3A’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is €95.77.
What is DE:KK3A’s upside potential, based on the analysts’ average price target?
Cytokinetics has 82.56% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Cytokinetics a Buy, Sell or Hold?
Cytokinetics has a consensus rating of Strong Buy, which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
What is Cytokinetics’s share price target?
The average share price target for Cytokinetics is €95.77. This is based on 17 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €125.54, and the lowest forecast is €69.95. The average share price target represents a 82.56% increase from the current price of €52.46.
What do analysts say about Cytokinetics?
Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Street analysts.
How can I buy shares of Cytokinetics?
To buy shares of DE:KK3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
